We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11,276.00 | 11,314.00 | 11,320.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8406 | 29.47 | 174.84B |
From Feb 2020 to Feb 2025
By Philip Waller
LONDON--Hutchison China MediTech Ltd (HCM.LN) on Tuesday reported positive results from a Phase II trial of a kidney cancer drug.
The group and its partner, AstraZeneca PLC (AZN.LN), said data from the continuing trial of savolitinib in patients with papillary renal cell carcinoma had shown early clinical benefit.
They said the data showed a clear efficacy signal and an encouraging long duration of response to the drug, which remained well tolerated.
Hutchison and AstraZeneca said the results supported initiation of a Phase III trial.
-rite to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
February 14, 2017 02:32 ET (07:32 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
